comparemela.com
Home
Live Updates
Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results : comparemela.com
Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Canada ,
Quebec ,
Pointe Claire ,
Canadian ,
Kaitlin Gallagher ,
Bruce Pritchard ,
Nicole Rusaw ,
Shrinal Inamdar ,
Exchange Commission ,
Prnewswire Liminal Biosciences Inc ,
Antagonist Development Plan ,
Securities Exchange ,
Agonist Development Plan ,
Liminal Biosciences Inc ,
Nasdaq ,
Nasdaq Capital ,
Chief Financial Officer ,
Gary Bridger ,
Interim Chief Scientific Officer ,
Chief Executive Officer ,
Strategic Advisor ,
Interim Chief Scientific ,
Nasdaq Capital Market ,
Nasdaq Listing Rule ,
Year Ended December ,
Securities Act ,
Securities Exchange Act ,
Liminal Bioscience ,
Canadian Securities Administrators ,
Annual Report ,
Associate Director ,
Investor Relations ,
Media Contact ,
comparemela.com © 2020. All Rights Reserved.